WGS as reported
GeneDx Holdings Corp. reported $443M of revenue over the trailing twelve months, +34% on the year before. 10 reported series are charted on this page, each one as filed.
$443M
Revenue, trailing twelve months · to Q1 2026 · +34% against the twelve months before
- Net Income
- −$78M
Net Income · +102% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- −$29M
Free Cash Flow · +119% year on year · trailing twelve months to Q1 2026
- Op Margin
- −16%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $443M | +34% | Q1 2026 |
| Net Income | −$78M | +102% | Q1 2026 |
| EPS | −$2.68 | +90% | Q1 2026 |
| Gross Margin | 69% | n/a | Q1 2026 |
| Op Margin | −16% | n/a | Q1 2026 |
| Net Margin | −18% | n/a | Q1 2026 |
| ROE | −9.1% | n/a | Q1 2026 |
| ROA | −4.7% | n/a | Q1 2026 |
| ROIC | −7.0% | n/a | Q1 2026 |
| Free Cash Flow | −$29M | +119% | Q1 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
GeneDx Holdings Corp. (WGS) - Revenue & ProfitRevenue & ProfitGeneDx Holdings Corp. (WGS)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Diagnostics & Research
Ranks #28 of 29 by Smart Score